Table 1 Patient demographics and baseline characteristics
Variable | Reversal group (n = 12) | Bleeding group (n = 38) |
|---|---|---|
Gender, n (%) | Â | Â |
   Male | 6 (50) | 28 (74) |
   Female | 6 (50) | 10 (26) |
Age, years; mean (SEM) | 67.3 (4.1) | 66.1 (1.8) |
Body mass index, kg/m2; mean (SEM) | 24.5 (1.2) | 23.4 (0.8) |
Bodyweight, kg; mean (SEM) | 74.7 (4.0) | 69.2 (4.7) |
Blood pressure, mm Hg; mean (SEM) | Â | Â |
   Systolic | 114.1 (7.3) | 92.1 (3.7) |
   Diastolic | 61.4 (5.2) | 48.1 (2.4) |
Heart rate, beats/minute; mean (SEM) | 102.4 (11.0) | 112.9 (4.9) |
Body temperature, °C; mean (SEM) | 37.2 (0.2) | 36.8 (0.3) |
Prior history of bleeding, n (%) | 4 (33) | 4 (11) |
Pre-treatment INR, mean (SEM) | 2.8 (0.2) | 1.7 (0.1)* |
Pre-treatment Quick value, %; mean (SEM) | 33.1 (2.7) | 54.7 (2.6)* |
Baseline laboratory assessments, mean (SEM) | Â | Â |
   Hemoglobin, g/dl | 11.8 (0.6) | 8.2 (0.3)* |
   Serum creatinine, mg/dl | 2.0 (0.5) | 1.3 (0.2) |
   Serum bilirubin, mg/dl | 3.3 (1.1) | 2.3 (1.2) |
   C-reactive protein, mg/dl | 8.7 (4.1) | 9.4 (1.8) |
Indication for vitamin K antagonist therapy, n (%) | Â | Â |
   Atrial fibrillation | 4 (33) | N/A |
   Heart valve replacement | 3 (25) | N/A |
   Pulmonary embolism | 1 (8) | N/A |
   Thrombosis prophylaxis | 1 (8) | N/A |
   Post-myocardial infarction | 3 (25) | N/A |
Use of low-molecular weight | Â | Â |
   heparin, n (%) | 2 (17) | 25 (66) |